A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF LANIFIBRANOR FOLLOWED BY AN ACTIVE TREATMENT EXTENSION IN ADULT PATIENTS WITH NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS 2 (F2)/FIBROSIS 3 (F3) STAGE OF LIVER FIBROSIS
- Registry ID
- 337HNAS20011
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- INVENTIVA S.A
- Start date
- 2024-04-19
- Last update
- 2021-07-16
Conditions
- NONALCOHOLIC STEATOHEPATITIS (NASH)
Related clinical trials
- A PHASE III DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL TO EVALUATE LIVER-RELATED CLINICAL OUTCOMES AND SAFETY OF ONCE WEEKLY INJECTED SURVODUTIDE IN PARTICIPANTS WITH COMPENSATED NON-ALCOHOLIC STEATOHEPATITIS/METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (NASH/MASH) CIRRHOSIS
- A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PHASE III TRIAL EVALUATING LONG-TERM EFFICACY AND SAFETY OF SURVODUTIDE WEEKLY INJECTIONS IN ADULT PARTICIPANTS WITH NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS/METABOLIC ASSOCIATED STEATOHEPATITIS (NASH/MASH) AND (F2) - (F3) STAGE OF LIVER FIBROSIS
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH)/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING
THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH NON-CIRRHOTIC
NONALCOHOLIC STEATOHEPATITIS (NASH)/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND FIBROSIS (SYNCHRONY-HISTOLOGY)
- A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFINOPEGDUTIDE (MK-6024) IN
ADULTS WITH PRECIRRHOTIC NONALCOHOLIC STEATOHEPATITIS
- A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFECT OF RESMETIROM ON LIVER-RELATED OUTCOMES IN PATIENTS WITH WELL-COMPENSATED (CHILD-PUGH A) NON-ALCOHOLIC STEATOHEPATITIS (NASH) CIRRHOSIS (MAESTRO-NASH OUTCOMES)
View on source registry